We’re excited to announce Kevin Bitterman has joined Atlas Venture as a partner!
Kevin is well known in the Boston biotech ecosystem, having spent the last dozen-plus years on the life science team at Polaris Partners. He brings a great mix of experiences, skills, and interests to the team, and is a superb fit with the group.
Kevin trained as a molecular biologist, getting a PhD in David Sinclair’s lab at Harvard where his work focused on chromatin silencing, cellular metabolism, and stress response pathways (the latter of which has helped him become a great board member). He also learned to appreciate the true joy of endlessly splitting HEK293 cells into new culture flasks, so understands both the inspiration and perspiration required in science. The desire to move those insights from bench to bedside – and the accompanying potential to impact patients – is what really drives him, and is a core belief we share here at Atlas. We all embrace science-first investing with the mission of “doing well by doing good”.
To sum up his venture experience, he’s a passionate early stage company-builder who is particularly excited by difficult-to-solve problems. As the founding CEO of Editas Medicine (NASDAQ:EDIT), Kevin was instrumental in creating and launching one of the leading gene editing companies (even if a direct competitor to our Intellia Therapeutics)! He’s also served as the founding CEO of other biotech startups, like Visterra and Morphic Therapeutic, and has been the founding investor in a number of others. Like the rest of us here at Atlas, Kevin enjoys rolling up his sleeves and helping build new biotech startups – confirming and consolidating early stage science, recruiting great teams of entrepreneurs and executives, helping to construct strong syndicates, and encoding the startups with the right long term vision and strategic “DNA” for success.
He’s built an incredibly strong reputation in the biotech community as a go-to venture investor and company-building partner in the true sense. Without exception, every entrepreneur, board member, and co-investor that we talked to about Kevin was effusive about his intellect and insight, broad-ranging contributions, and positive influence in the boardroom.
Kevin was attracted to Atlas’ evolution into a biotech-only firm, focused on seed-led venture creation in a flat and equal partnership. That said, it’s worth mentioning that he learned the art of venture capital at one of the top firms in the business, Polaris Partners, where he worked closely with industry leaders like Terry McGuire, one of Kevin’s most important mentors. We’ve worked closely with the Polaris team over the years and we’re hopeful that Kevin joining us will further strengthen the connection between our firms.
Lastly, Kevin’s also a fierce competitor who can’t stop moving. Whether its race car driving, skiing fast and furious, or running distances on roads and trails, Kevin has a strong bias to action. Many in the “Atlas family” have had the pleasure of running with him – as he’s been a core member of the Atlas’ Reach The Beach relay team (“Runners, Drugs, and Money”), trekking 200-miles through the woods of NH multiple times over the past few years. Although he has a soft-spoken and sophisticated appearance, his running playlist screams otherwise (think Metallica’s The Four Horsemen), tunes that definitely crank up the heart beat and the pace, not that Kevin actually needs to move more, or faster.
On a more personal note, we joined the venture business at the same time back in 2004-2005, and although we’ve never done a deal together, we’ve become good friends over the past dozen years. He was one of my first connections in the Boston ecosystem, and a frequent sounding board around both firm and startup topics over time. In addition to being a stellar venture investor, he’s an exceptionally good human being with his head screwed on straight – just the sort of person we’d all like to spend the next couple decades working with side by side.
On behalf of the Atlas team and partnership, we’re thrilled to welcome him onboard – and are looking forward to many years of building great biotech startups together!
Lightning can definitely strike the same place twice, or so it seems in biotech. The latest example is True North Therapeutics’ recent acquisition by Bioverativ for its program addressing cold agglutinin disease, a type of rare autoimmune hemolytic anemia: it was a startup born out of a prior acquisition, where it was spun-out of iPerian following the latter’s purchase by BMS.
This acquisition-spinout-acquisition dance move solves for an important macro issue in biotech deal-making: in a multi-asset portfolio, one buyer may not want all the assets, or only assigns marginal value to them. This frequently leads to the suboptimal scenario of selling the entire company so that the buyer can get the lead asset, but not getting “full” value for the rest of the portfolio. These post-acquisition spinouts addresses the common “asymmetry of maturity” around R&D-stage portfolios in many biotech companies: the lead program is usually much further along in the R&D process, and thus drives the majority of the imputed value by the Pharma buyer while the other less mature programs go unappreciated. Negotiating to spinout the other assets at the time of the acquisition is one solution to this problem, but it’s not without its challenges.
Before sharing some thoughts on the overall approach, it’s worth sharing more color on the recent example of iPerian/True North for context. iPerian was started in 2009 as a merger of an East and West coast startups, Perian and iZumi Bio respectively, in order to develop drugs based on iPS cells. iPerian raised ~$80M over the next five years, in the latter part pivoting its business plan into antibody development. It’s lead program was an anti-tau antibody that BMS acquired in April 2014 for neurodegenerative conditions. As part of the asset acquisition, the team at iPerian spun-out their 2nd program, a C1 inhibitor called TNT009, into a new startup called True North. This new entity was launched with a Series A financing in June 2014 of $22M to fund development TNT009 in a set of rare diseases. According to Crunchbase, most, if not all, of the original iPerian investors participated: Kleiner Perkins, MPM, SR One, and several others. In 2015-2016, True North raised an additional $120M from blue-chip later stage and crossover investors, in three equity financings, to power up this asset-centric story, bringing TNT009 successfully into Phase 2 with an eye on taking it all the way. Bioverativ, in search of additional pipeline, acquired it earlier this week to “complement” its hemophilia business.
Getting two bites at the apple can help juice up the returns for all the shareholders. iPerian was acquired for $175M on a total equity raise of ~80M, a reasonable ~2x average multiple for a story that pivoted significantly from its founding thesis. Up to $550M in future milestones were promised, though BMS recently out-licensed the asset to Biogen (Bioverativ’s parent, funnily enough), so it is unclear how much of those economics were transferred to Biogen (versus being renegotiated as is often the case). For True North, it was acquired for $400M upfront, with up to $425M more in milestones, representing a good multiple on the invested capital over just a few years. Across both, an aggregate of $220M went into these assets for $575M in upfront value and up to $975M in milestones – roughly $1.5B in value. Some portion of this will go back to the original iPerian investors (through their initial ownership in the spinout and the equity they purchased along the way). Hard not to like those return numbers.
This isn’t a one-off example. This acquisition-and-spinout model has worked very successfully with other multi-asset stories as well.
Aragon/Seragon is a fantastic recent example. Rich Heyman definitely made lightning strike twice, as Xconomy noted (here). Aragon developed a new prostate drug against the androgen receptor, which J&J bought, and Seragon worked on breast cancer via the estrogen receptor, which Genentech/Roche bought. The combined pair of parent/spinout raised only ~$150M in equity capital and generated nearly $1.4B in upfront payments and up to another $1.4B in milestones.
A decade ago, when Amgen bought kidney disease Ilypsa in 2007 for $420M, a spinout called Relypsa emerged with earlier stage assets a few months later. Relypsa went on to go public and then get bought for $1.5B in 2016 by Galenica. Combined, Ilypsa/Relypsa raised $400M or so in private and public equity capital, and generated nearly $2B of value. Also over a decade ago, the Conforma/Cabrellis two-step was a great pair of returns when Biogen and Pharmion stepped up to acquire the parent and spinout within six months of eachother.
Other spinouts are “in the works” and hoping to get struck by lightning a second time: In 2015, after Naurex was acquired by Allergan, Aptinyx was spun out to focus on early stage NMDA modulation (here). Allergan also bought Taris Medical in 2015 for its lead bladder program, and Taris “2.0” was spun-out a few months later (here). And it doesn’t just happen with startups: J&J’s $30B acquisition of Acetlion will involve a large and well-capitalized spinout of an R&D NewCo with Actelion founder Jean-Paul Clozel as CEO.
Of course, the strategy doesn’t always work. Some of the progeny from prior spinouts have died or simply fallen off the radar: Novacardia/Sequel, Serenex/Coserics, Sirion/Revision, and many other parent/spinouts haven’t gotten hit with lightning twice. Such is the nature of drug R&D.
Stepping back to the big picture though, it’s clear this approach can create lots of additional value versus just leaving an under-appreciated asset in the buyer’s hands. Spinning out assets can bridge the gap on the upfront value between buyers and sellers, and harness the asymmetric information that a motivated management team may have about the unappreciated value of the other programs. Openness to a team’s desire to spin out the early stage assets can also be a differentiator amongst buyers in a competitive situation.
But the acquisition-spinout model isn’t always simple. Talking to Bill Collins, Kingsley Taft, and Mitch Bloom at Goodwin Procter, there are several things to think about regarding these models:
Biotechs being bought need to fight hardfor these early in a deal negotiation, before “anchoring” has set in on the part of buyers around the terms. Making this a core guidance principle of a deal in early discussions can be very enabling. Trying to throw this in at the end of the deal is typically not productive.
Spinouts at the time of the sale work best when the assets are clearly distinguishable. Entanglements related to shared IP or platform insight can make these difficult to do. Discrete programs, with asymmetric maturity, make it “easiest” to do.
Tax issues are hugely important as the spinout event creates a tax liability for the shareholders – it’s a taxable event to the extent that the spun out assets forming the NewCo have more than residual value. If the value is relatively high, the incurred tax will be high, and in many cases those spinouts just don’t happen. Understanding the tax nuances around value of the assets, and any potential NOLs to utilize, at the time of the spinout is important. Asset purchases (as different by equity purchases) can also factor into the structure.
Spinouts need to re-form an investor syndicate and complete a financing transaction to capitalize the NewCo. As part of this, and related to the tax question, the “pre-money” value needs to be agreed on in a manner appropriate with fiduciary responsibilities to all shareholders. Given the sensitivity around this, especially with non-participating syndicate members and prior founders/team members, having an investor and executive group that likes working together and is on the same page is key.
Management team expectations are real considerations. If the buyer wants key leadership team members to help drive the asset’s development forward post-closing, clear expectations (and agreements) around who is doing what in the spinoff versus remaining at the buyer need to be established, including “employee sharing” or transaction services arrangements.
It’s worth noting that another solution, perhaps more elegant, than the acquisition-spinout model is to plan for it in advance by utilizing the LLC-holding company structure where the individual assets are already in their own respective subsidiary C-corps. By converting to this model early in the life of a company, a biotech preserves all the traditional upside of a C-corp while retaining the benefits of selling individual assets. Nimbus Therapeutics sold its NASH program targeting acetyl Co-A carboxylase, housed in its Nimbus Apollo subsidiary, to Gilead in the spring of 2016 via this approach. All the other Nimbus programs continued to move forward without pause from the Gilead/ACC transaction.
It’s hard to argue that two (or more) bites at the apple aren’t better than one – so optimizing the opportunity to get that additional bite can be a big value creation lever for emerging biotechs.
The FDA recently approved Imfinzi (durvalumab) for the treatment of bladder cancer, making it the fifth new monoclonal antibody approved this year. More than twenty antibodies have been approved by the FDA since 2015. While not quite the magic bullet envisioned
Neural networks, cloud computing, deep learning, and in silico wizardry are on the cusp of disintermediating pharmaceutical drug discovery, cutting billions of billions off the industry’s cost of new drugs and reducing the time to get new medicines approved to
Two key geographic clusters dominate the biotech landscape today. These two areas, Boston and San Francisco, combine a unique blend of biomedical science, venture capital, entrepreneurial talent, risk-taking culture, and geographic density. Other regions have some or all of these
This guest blog was written by Troy Lister, Head of Chemistry, and Cristina Larkin, Chief Commercial Officer, of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. A national security threat equivalent to terrorism? This is how
As a biotech investor, it’s been fascinating to watch the Snapchat IPO and the fanfare around this $25B sensation following its offering as a “camera” company. As one of the big tech unicorns, it’s justifiably gotten considerable attention in the
Despite the volatility of biotech stocks in the public markets, the VC-backed private biotech ecosystem has been in remarkable equilibrium for much of the last decade. e·qui·lib·ri·um. noun. a state in which opposing forces or influences are balanced. As I’ve noted
Snow sports are a passion of mine; almost any day up on a mountain is a great day. By combining this passion with a bigger purpose, I’ve recently tapped into a true vein of inspiration, integrating both my professional and
President Trump’s tenure as the 45th POTUS has begun with even more fireworks than most pundits predicted – protests, marches, bans, and lots of other drama. The coastal Twitter/Facebook bubbles are exploding with anger and rage, while the Trump populists
Today Celgene announced its acquisition of Delinia for $300 million upfront, and up to $475 million in milestones, adding to its growing portfolio of novel immunology medicines. Delinia’s rapid trajectory over the past fifteen months has been exciting to watch: this
Today Allergan announced a transformative deal with Lysosomal Therapeutics (LTI), an emerging biotech focused on Parkinson’s Disease through an understanding of human genetics and sphingolipid biology (here). This deal brings a new chapter for LTI as we move our lead
Good riddance to 2016, and a warm embrace to 2017 – or so is the sentiment of most biotech investors as they head into the 35th annual JPM Healthcare Conference. Many have bemoaned last year as an abysmal one for
Pharma R&D productivity continues to be a critical issue for the industry. Making smart investments in R&D requires an understanding of the risk and return drivers across the product development cycle, as well as some good fortune. This week the
Earnout payments have been nearly ubiquitous in biotech M&A transactions for the past decade. Given the risks, costs, and timelines in drug R&D, these contingent value rights, or “biobucks”, play an important role in bridging the gap in valuation expectations
Everyone wants to invest in a Unicorn, or so it seems. These are the investments that legendary track records are made of. But truth be told, Unicorns don’t always lead to the biggest pots of gold at the end of
Venture capital has been on a good run over the past few years across a range of sectors; even with recent slowdown relative to 2014-2015, venture-backed investments remain above historic averages. In fact, the first three quarters of 2016 alone
A biotech’s Board often plays important roles in shaping the company’s success or failure: contributing strategic guidance, providing proper governance, stewarding fiduciary responsibilities, raising a startups’ profile, aiding business development, to name a few. Over the life of a biotech,
Fund flows between sectors are a critically important dynamic in the equity capital markets: when net fund flows are positive, more demand for equity exists and stock price movement bias upwards; conversely, when fund flows are negative, the selling pressure
A new FDA approval marks a major milestone in the biopharmaceutical business; relatively few biopharma companies are ever able to lay claim to having discovered, developed, or marketed a recently approved medicine. As of mid-October, the FDA has approved 17
Although many wrote off the biotech IPO markets as moribund earlier in 2016, the sector has been quietly issuing a steady stream of new offerings. Despite the volatility related to drug pricing, and disastrous first six-weeks of the year, we’ve
As larger Pharma externally-enables more of its pipelines, the cadence of biotech M&A appears to be accelerating, especially for early stage deals. Another week, another biotech acquisition in the news: Allergan has acquired two private and two public R&D-stage companies in just
The maelstrom around drug pricing has continued its fury over the past month, which has led to considerable volatility in the biopharma stock market. Investor fears of draconian price controls that will eliminate the return of investment from innovative pharmaceutical
Pharmaceutical pricing got thrown onto the front page again last week, causing the expected anaphylactic reactions among politicians, practitioners, and parents. The root of this crisis: Epipen’s 600% price increase over the past eight years. The biannual upticks underlying that
Biotech has been one of the hottest sectors in the venture capital asset class over the past few years. Strong IPO and M&A markets have put wind in the sails of the space since 2012, and robust investment activity has
After five very strong years, biotech as a sector has struggled to catalyze positive investor sentiment so far for the past twelve months. In a disastrous start to the year, the NASDAQ Biotech Index shed 30% in just the first
With the big cancer confab ASCO 2016 fading into memory, R&D teams everywhere are getting back to work on their cancer programs – and across the industry many of them will be doing the same work, on the same targets,
CRISPR/Cas genome editing has captured the attention of the popular media, scientific community, and the investment world: the promise of going into a cell and precisely making changes in their genetic code to cure them of illness is certainly captivating.
Jumping into a first-time CEO role in an emerging biotech is a daunting but exciting opportunity – both for the newly-minted chief executive and their Board of Directors. A great hire can be positively catalytic to a startup; and, sadly,
Startup ecosystems supported by venture capital are defined by dynamism, with the creation, growth, exiting, or failure of new innovative companies conspiring to keep these entrepreneurial landscapes in constant change. Investor returns and sentiment are dramatically impacted by how these
University tech transfer offices play a central role in the biotech ecosystem, as the successful commercialization of an academic discovery is the aspiration of many young startups. Navigating – and optimizing – this tech transfer process is therefore critical to the
Last week, when the Treasury effectively scuttled the Pfizer-Allergan merger, there was much rejoicing: politicians and pundits alike were thrilled that tax inversion greed had been stopped, and that companies like Pfizer would have to “pay their fair share.” Investors
Today Gilead announced the acquisition of Nimbus’ lead program targeting NASH and related metabolic disorders for $400M upfront and up to another $800M in development and regulatory milestones (here). This transformative deal is the culmination of over five years of work on
Today we announced the acquisition of Padlock Therapeutics by BMS for up to $600M in total deal value (here), bringing a bittersweet end to a great startup story and the start of a promising and likely productive portfolio for BMS.
For startup and emerging biotech companies, corporate venture capital and direct corporate equity investing are critically important contributors on the spectrum of funding sources – and over the past fifteen years, their involvement as investors in young biotech companies appears
It’s hard to believe how time flies, but I started this LifeSciVC biotech-blogging experiment five years ago today. Since that initial post in March 2011, exactly 250 blogs have gone live, making it an opportune time to step back and
Biotech and the overall equity markets have been under siege the past few months from macro forces, like oil and the economy, as well as sector-specific concerns like drug pricing. After watching the carnage in 2016 wreck havoc with small
The equity markets have softened tremendously in recent weeks and the NASDAQ Biotech Index has swooned to levels last held in late 2014, in line with other equity indices like the S&P500. Triggered by significant and negative macro forces, this
2015 was the biggest year ever for venture capital funding into the biotech sector. According to the latest MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), with data from Thomson Reuters, over $7.4B was invested during the year. Lots
It’s that time of the year again. As part of the annual pilgrimage, acolytes of the healthcare investment community are about to descend upon the Union Square area of San Francisco. As part of the ritual of the 34th Annual
The past five years have been the greatest bull run in the history of the biotech industry. Stock market outperformance, significant fundraising levels both private and public, more IPOs in this window than ever before, and huge volumes of M&A.
We’re excited to announce two new collaborations today from our neuroscience portfolio – Quartet with Merck (here) and Rodin with Biogen (here) – to advance their programs into early clinical development. These are both young companies that we helped create